Treatment Outcomes of Sunitinib Treatment in Advanced Renal Cell Carcinoma Patients: A Single Cancer Center Experience in Korea

Min Hee Hong; Hyo Song Kim; Chan Kim; Jung Ryun Ahn; Hong Jae Chon; Sang-Joon Shin; Joong-Bae Ahn; Hyun Cheol Chung; Sun Young Rha

doi:10.4143/crt.2009.41.2.67

Articles

Page Path: HOME > Cancer Res Treat > Volume 41(2); 2009 > Article

Original Article Treatment Outcomes of Sunitinib Treatment in Advanced Renal Cell Carcinoma Patients: A Single Cancer Center Experience in Korea: Min Hee Hong, M.D.^1,2,3, Hyo Song Kim, M.D.^1,2,3, Chan Kim, M.D.^1,2,3, Jung Ryun Ahn, M.D.^1,2,3, Hong Jae Chon, M.D.^1,2,3, Sang-Joon Shin, M.D.^1,2,3, Joong-Bae Ahn, M.D.^1,2,3, Hyun Cheol Chung, M.D., Ph.D.^1,2,3, Sun Young Rha, M.D., Ph.D.^1,2,3; Cancer Research and Treatment : Official Journal of Korean Cancer Association 2009;41(2):67-72.
DOI: https://doi.org/10.4143/crt.2009.41.2.67
Published online: June 30, 2009

¹Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.

²Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea.

³Yonsei Cancer Center, Yonsei University Health System, Seoul, Korea.

Correspondence: Sun Young Rha, M.D., Ph.D. Department of Internal Medicine, Yonsei University College of Medicine, 134 Shinchon-dong, Seodaemun-gu, Seoul 120-752, Korea.
Tel: 82-2-2228-8050, Fax: 82-2-362-5592, rha7655@yuhs.ac

• Received: April 12, 2009 • Accepted: May 19, 2009

12,699 Views
74 Download
57 Crossref

prev next

Full Article

Download PDF

Abstract

Purpose
The retrospective study was performed to assess the efficacy and toxicity profiles of sunitinib in Korean patients with metastatic renal cell carcinoma (RCC).
Materials and Methods
Between January 2005 and December 2008, 76 Korean patients with recurrent/metastatic RCC who received sunitinib were retrospectively reviewed. The primary end point was progression-free survival and the secondary end points were overall survival and response rate. We also assessed the toxicities associated with sunitinib treatment.
Results
Of the 76 patients, 69 (90.1%) were diagnosed with clear cell RCC. The median progression-free survival and overall survival were 7.2 and 22.8 months, respectively in overall patients. Sixty-two patients (81.6%) received 50 mg 4 week and 2 week off schedule, and 14 patients (18.4%) received 37.5 mg daily on a daily continuous schedule. The objective response rate and disease control rate were 27.6% and 84.2%, respectively. A dose reduction or reduction in dose due to adverse events occurred in 76% of the patients, whereas 11% of the patients had discontinued treatment. Other common laboratory abnormalities were increased serum creatinine (75.6%), elevated alanine aminotransferase (71.0%), neutropenia (61.8%), anemia (69.7%), and increased aspartate aminotrasferase (53.3%). Grade 3/4 toxicities occurred as follows: thrombocytopenia (38.2%), fatigue (10.5%), stomatitis (10.5%), and hand-foot syndrome (9.2%).
Conclusion
Our results indicate that sunitinib treatment is effective and tolerable for ecurrent/metastatic RCC patients in Korea. Further studies with prognostic or biochemical factors are needed to clarify the different toxicity profiles of this study.
Key words: Renal cell carcinoma, Sunitinib, Korea, Efficacy, Toxicity

Introduction

Renal cell carcinoma (RCC) represents 2~3% of all tumors with an incidence which is increasing annually (1). Up to 30% of RCC patients present in an advanced state, and approximately 40% of patients who undergo curative surgical resection experience recurrence during the follow-up (2,3). Though cytokine treatment with interleukin-2 or interferon-alpha has been widely used as a first-line treatment of metastatic RCC, it has shown a modest survival benefit and a poor quality of life (4). Therefore, alternative agents with greater efficacy and less toxicity are needed for the systemic treatment of renal cell carcinoma. Remarkable improvement in understanding the biology and genetics of RCC has facilitated the novel target-based approaches for the treatment of metastatic RCC.

Sunitinib is an orally available, multi-targeted tyrosine kinase inhibitor which specifically interferes with platelet-derived growth factor receptor and vascular endothelial growth factor receptor (5). These receptor tyrosine kinases are known to play important roles in the pathogenesis of RCC (6,7). In phase III trials, this agent was shown to significantly improve the median progression-free survival (PFS), and yield a higher response rate (RR), and afford a better quality of life over interferon-alfa (8). However, these studies were performed mainly in Western populations. Therefore, further studies about the efficacy and safety profiles are needed for involving Asian RCC treated with sunitinib.

We retrospectively performed this descriptive study to assess the efficacy and toxicity profiles of sunitinib to determine whether there is a difference in Korean patients with metastatic RCC compared to Western patients.

Materials and Methods

1. Patients

The medical records of RCC patients with recurrent or metastatic disease who had received sunitinib treatment at the Yonsei University Health System (YUHS) between January 2005 and December 2008 were retrospectively reviewed. The inclusion criteria were as follows; Asian ethnicity, metastatic RCC treated with sunitinib, and patients with available medical data for evaluating efficacy and toxicity. Clinicopathologic factors such as age, gender, tumor histology, Eastern Cooperative Oncology Group performance status (ECOG PS), the number of prior treatments, sites of metastasis, laboratory findings, and patient survival were collected retrospectively and analyzed. We also assessed the Memorial Sloan-Kettering Cancer Center (MSKCC) risk scoring system according to a previous study (9).

2. Sunitinib treatment

Sunitinib was prescribed as a part of clinical or non-clinical trials with 2 different schedules: group 1, 50 mg orally once daily for 4 weeks followed by a 2 week rest period (50 mg 4 weeks on - 2 weeks off schedule); and group 2, 37.5 mg daily continuous dosing. For the evaluation of the response, Response Evaluation Criteria In Solid Tumors (RECIST) was applied (10). Regular physical examinations and computed tomography or magnetic resonance imaging were performed for treatment outcome every 6~8 weeks. Toxicity was evaluated during the sunitinib treatment according to the National Cancer Institute common toxicity criteria (version 3.0).

3. Statistical analysis

Survival analysis was calculated using the Kaplan-Meier method with Statistical Package for the Social Sciences (SPSS), version 15.0. PFS was defined from the date of the 1^st dose of sunitinib to the death of any cause or disease progression. Overall survival (OS) was defined from the date of the 1^st dose of sunitinib to the death of any cause. We also analyzed the 1-year PFS rate and OS rates. Toxicities were estimated as simple proportions.

Results

1. Patient characteristics

Seventy-six RCC patients were included in the analysis (Table 1). The median age was 57.5 years (range 29~73 years), and the patients consisted of 63 males (82.9%) and 13 females (17.1%). Sixty-five patients (85.5%) were diagnosed with clear cell RCC and the others diagnosed with papillary (n=4), chromophobe (n=2), and mixed cell types (n=4; 2 patients with clear cell combined with papillary cell, 1 patient with clear cell combined with granular cell, and 1 patient with sarcomatoid type combined with clear cell). The distribution of MSKCC scores of 60 patients with evaluable data were as follows: favorable for 7 patients (11.6%), intermediate for 47 patients (78.3%), and poor for 6 patients (10%). The previous treatments were as follows: previous nephrectomy in 72 patients (94.7%), conventional chemotherapy in 16 patients (21.1%), cytokine treatment in 42 patients (55.3%), targeted agent in 7 patients (9.2%), and radiotherapy in 16 patients (21.1%). The number of patients who underwent nephrectomy as a curative aim was 35 (46.1%) and pathologic staging in completely resected patients was as follows: stage I for 6 (24.0%), stage II for 8 (32.0%), stage III for 9 (36.0%), and stage IV for 2 (8.0%) with available pathologic data (25 patients). The metastatectomy was performed in 4 patients and it included lung segmentectomy, retroperitoneal lymphadenocetomy, colon resection and splenectomy with distal pancreatectomy. 5 patients were treated with sorafenib and two with erlotinib/ bevacizumab before sunitinib treatment. Number of disease sites was as follows: 0 for 1 patient (1.3%), 1 for 17 patients (22.4%), 2 for 25 patients (32.9%), and >2 for 34 patients (43.4%), respectively. Most prevalent site of metastasis were the lung (56 patients [73.7%]) followed by the lymph nodes (36 patients [47.4%]), bone (29 patients [38.2%]), and liver (8 patients [10.5%]).

2. Treatment summary and survival outcome

Two different settings in the treatment schedule existed. The majority of the patient (n=62 [81.6%]) received the standard regimen of 50 mg 4 weeks on - 2 weeks off schedule, and 14 patients (18.4%) received the 37.5 mg daily schedule. The number of the patients who received sunitinib as a first-line systemic treatment were 31 (40.8%). After a median of 16.0 months (range, 0.5~40.1 months) of follow-up, 34 patients (44.7%) remained alive with diseases. The median treatment duration was 7.2 months (range, 0.5~35.7 months), and treatment is ongoing in 10 patients (13.2%). The reasons for treatment discontinuation were progressive disease (n=54 [81.8%]), and adverse events (n=7 [10.6%]). Other reasons of dose discontinuation included withdrawal of consent (4 patients) and loss to follow-up.

The median PFS was 7.2 months (95% confidence interval [CI], 4.7~9.7 months, Fig. 1), and the median OS was 22.8 months (95% CI, 18.7~26.9 months, Fig. 2). The 1-year PFS rate and 1-year OS rate were 36.8% (95% CI, 26.1~48.7%) and 61.8% (95% CI, 50.0~72.6%), respectively. Of the 786 evaluable patients, objective RR (including complete and partial responses) was 27.6% (95% CI, 18.0~39.1%) and the disease control rate (including complete response, partial response, and stable disease) was 84.2% (95% CI, 74.0~91.6%), as shown in Table 2. In 10 non-clear cell type RCC patients, 1 patient had a partial response (10%) and disease control was achieved in 8 patients. The median PFS was 5.1 months (95% CI, 4.2~6.0 months) and the median OS was 9.0 months (95% CI, 0.5~17.4 months) in the non-clear cell patients. In addition, in the subgroup who had prior targeted agent treatment (7 patients), 6 patients reached stable disease with 1.5 months (95% CI 0.0~6.7 months) of the median PFS and 12.0 months (95% CI, 1.4~22.5 months) of the median OS. We also evaluated the difference between dosing schedule. The response rate was 25.8% and the disease control rate was 82.3% in the 50 mg 4 weeks on - 2 weeks off dosing schedule, as compared with 35.7% and 92.9%, respectively, in the 37.5 mg daily treatment schedules (Table 2). The median PFS in both the standard and other dosing schedules was 7.2 months.

3. Toxicity

A total 76% of the patients had a dose interruption or dose reduction due to adverse events, whereas only 11% of patients discontinued treatment due to toxicity. Stomatitis and diarrhea were the most commonly reported treatment-related adverse events (63.2% and 60.5%, respectively), but the rate of severe cases with grade 3 or more was not prevalent (10.5% and 6.6%, respectively), as shown in Table 3. Adverse events which were reported with a > 50% frequency were fatigue (57.9%), anorexia (59.2%) and hand-foot syndrome (52.6%). A decrease in the left ventricular ejection fraction of grade 1 was reported in only 1 case, and was without clinical significance. Thyroid function tests were conducted in 45 patients. Eleven cases (24.4%) of hypothyroidism were noted, and 8 (17.8%) patients needed thyroid hormone replacement. In addition, we did not observev hemolytic uremic syndrome or thrombotic thrombocytopenia purpura in this group of patients (11).

The most common laboratory abnormality was thrombocytopenia (77.6%), and 38.2% of the patients experienced grade 3 or 4 thrombocytopenia, which was no clinical significance (such as bleeding; Table 4). Other common laboratory abnormalities were increased serum creatinine (75.6%), elevated alanine aminotransferase (71%), neutropenia (71.1%), anemia (69.7%), and increased aspartate aminotrasferase (53.3%). Grade 3 or 4 hyperamlyasemia was reported in 13.3% of patients, but no signs of clinical pancreatitis were observed.

Discussion

RCC is one of the malignancies with a dismal prognosis because of the modest response to conventional chemotherapeutic agents and cytokine therapy. With the elucidation of the molecular pathogenesis of RCC, sunitinib, one of the molecular targeted agents was introduced for the treatment of metastatic RCC (8,12). Previous studies have confirmed the promising efficacy of sunitinib as a standard first-line treatment for metastatic clear cell RCC (8,12). However, these studies were mainly performed for patients in Western countries. Only one small study was reported for Asian patients with RCC who were treated with sunitinib (13), thereby the potential ethnic difference in the efficacy and toxicity of sunitinib have not been established. This retrospective study showed that homogeneous Asian patients with metastatic or recurrent RCC who received sunitinib had comparable survival outcome with patients in previous randomized studies.

For the treatment outcome, the median PFS and OS were 7.2 and 22.8 months, respectively. We also showed a 27.6% objective response rate and an 84.2% disease control rate in this analysis. Previous global trials have demonstrated 8.3 and 11 months of the median PFS and objective response rate of 34% and 31% (8,12). Even though it is difficult to compare this retrospective study with previous phase III randomized trials, we observed that metastatic RCC patients in our study also benefitted from sunitinib treatment. Interestingly, in our study, more patients with poor prognostic factors were included. In terms of MSKCC risk group, 88.3% of patients were in the intermediate or poor groups in this study. In addition, unlike the reported randomized studies, >50% of patients had an ECOG PS 1, and 8 (10.5%) patients with an ECOG PS 2 were also included. Therefore, considering the selection bias of randomized controlled trials which includes relatively better performance status, this finding may reflect more reliable results in real clinical practice with possible benefit from sunitinib treatment for metastatic RCC patients.

In terms of non-hematologic toxicity profiles, stomatitis was the most frequent adverse event in our study, which accounted for 63.2% of the cases; however grade 3 or 4 stomatitis accounted for 10.5% and was manageable. Meanwhile, more stomatitis and hand-foot syndrome were noticed in our study compared to the global trials. For hand-foot syndrome, a much higher rate of all grades and grade 3/4 toxicities (52.6% of all grades, 9.2% of grade 3 or 4) were noted in contrast to the previous trials (15~20% of all grades; 1~7% of grade 3 or 4). Similarly, for stomatitis, a much higher toxicity (63.2% of all grades; 10.5% of grade 3/4) was noted than in previous trials (13~25 % of all grades; 1~5 % of grade 3 or 4).

Hematologic toxicity, especially for thrombocytopenia, was more remarkable in this study. All grades of thrombocytopenia were 77.6%, and it was similar with Western data (8,12). However, patients in the present study experienced a much higher rate of grade 3 or 4 thrombocytopenia (38.2% in YUHS data versus 8% in the randomized phase III trial, respectively). In addition, thrombocytopenia was the most common cause of dose reduction, delay, and discontinuation in our study. Other grade 3 or 4 hematologic toxicities such as neutropenia (28.9%), anemia (23.7%), and leukopenia (18.4%) were also more frequent than in Western analyses. This finding was consistent with Japanese study involving sunitinib treatment (13). Whether this toxicity is directly related to host factors such as poor PS, or prior numbers of treatments remains uncertain. A disparity in the toxicity profiles between Eastern and Western countries has been in colon cancer patients who received capecitabine (14-16). Compared to Caucasians, a higher incidence of hand-foot syndrome and a lower rate of diarrhea occurred in non-Caucasian patients treated with capecitabine, suggesting an ethnic difference between Western and Eastern patients. As shown in patients receiving capecitabine treatment, this finding may be caused by ethnic differences. Therefore, these descriptive results should be interpreted cautiously and further study with a larger sample size and pharmacokinetic tests are needed to clarify this finding.

The current single center retrospective analysis had several limitations. The patients in this retrospective study consisted of a heterogenous population. Thirteen percent of the patients had non-clear cell RCC, and 9% of all patients had already received targeted agents before sunitinib.

Nevertheless, this study represents one of the few studies in which sunitinib treatment was evaluated for efficacy and toxicity in Asian patients with RCC. Our results indicated that sunitinib treatment was effective and tolerable in Korean patients with metastatic RCC. Further studies with biochemical data would further clarify the clinical significance of theses findings.

Conclusion

This study assessed sunitinib treatment for recurrent/metastatic Korean patients with RCC in terms of efficacy and toxicity. PFS, OS, and RR in Korean patients was compatible to Western patients, although some toxicities in Korean patients were more frequent and severe, but were manageable.

NOTES

This study was supported by a faculty research grant of Yonsei University College of Medicine for 2007.

REFERENCES

1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137–2150. PMID: 16682732Article PubMed
2. Jemal A, Murray T, Ward E, Samuels A, Tiwari R, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10–30. PMID: 15661684Article PubMed
3. Janzen NK, Kim HL, Figlin RA, Belldegrun AS. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am. 2003;30:843–852. PMID: 14680319Article PubMed
4. Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol. 2007;25:884–896. PMID: 17327610Article PubMed
5. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU11248 Inhibits KIT and platelet-derived growth factor receptor β, in preclinical models of human small cell lung cancer. Mol Cancer Ther. 2003;2:471–478. PMID: 12748309Article PubMed
6. Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet. 1994;7:85–90. PMID: 7915601Article PubMed
7. Iliopoulos O, Levy AP, Jiang C, Kaelin WG Jr, Goldberg MA. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci USA. 1996;93:10595–10599. PMID: 8855223Article PubMed PMC
8. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon α in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115–124. PMID: 17215529Article PubMed
9. Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol. 2004;22:454–463. PMID: 14752067Article PubMed
10. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205–216. PMID: 10655437Article PubMed
11. Choi MK, Hong JY, Jang JH, Lim HY. TTP-HUS associated with sunitinib. Cancer Res Treat. 2008;40:211–213. PMID: 19688133Article PubMed PMC PDF
12. Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006;295:2516–2524. PMID: 16757724Article PubMed
13. Uemura H, Shinohara N, Naito S, Akaza H. A phase II study of the efficacy and safety of sunitinib in treatment-naive and pretreated Japanese patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2008;26:15S(Abstr 16108)Article
14. Law CC, Fu YT, Chau KK, Choy TS, So PF, Wong KH. Toxicity profile and efficacy of oral capecitabine as adjuvant chemotherapy for Chinese patients with stage III colon cancer. Dis Colon Rectum. 2007;50:2180–2187. PMID: 17963003Article PubMed
15. Yen-Revollo JL, Goldberg RM, McLeod HL. Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines? Clin Cancer Res. 2008;14:8–13. PMID: 18172246Article PubMed
16. Saif MW, Sandoval A. Atypical hand-and-foot syndrome in an African American patient treated with capecitabine with normal DPD activity: Is there an ethnic disparity? Cutan Ocul Toxicol. 2008;27:311–315. PMID: 19037763Article PubMed

Fig. 1

Progression-free survival in Korean patients with metastatic renal cell carcinoma.

Fig. 2

Overall survival in Korean patients with metastatic renal cell carcinoma.

Table 1

Patient characteristics

^*Data of cell type in one patient was missing. ^†Eastern Cooperative Oncology Group, ^‡Risk factors in Memorial Sloan-Kettering Cancer Center (MSKCC) risk scoring system are a low hemoglobin level, an elevated corrected calcium level, an elevated serum lactate dehydrogenase level, a poor performance status and an interval of less than 1 year between diagnosis and treatment. The MSKCC risk factors could not be calculated in 20 patients due to incomplete data.

Table 2

Best tumor response^*

^*Tumor response was assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST).

Table 3

Treatment-related adverse events

^*These data were available on selected 45 patients.

Table 4

Treatment-related laboratory abnormalities

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

pH-Responsive Block Copolymer Micelles of Temsirolimus: Preparation, Characterization and Antitumor Activity Evaluation
Ling Wang, Fangqing Cai, Yixuan Li, Xiaolan Lin, Yuting Wang, Weijie Liang, Caiyu Liu, Cunze Wang, Junshan Ruan
International Journal of Nanomedicine.2024; Volume 19: 9821. CrossRef
Comparative Evaluation of Safety and Efficacy of Alternate Schedule (AS) of Sunitinib in Asian and Non-Asian Patient Population for the Treatment of Metastatic Renal Cell Cancer (mRCC): A Meta-Analysis
Amit Joshi, Ishan Patel, Pratiksha Kapse, Manmohan Singh
Kidney Cancer.2022; 6(1): 37. CrossRef
High Serum Levels of IL-6 Predict Poor Responses in Patients Treated with Pembrolizumab plus Axitinib for Advanced Renal Cell Carcinoma
Yun Beom Sang, Hannah Yang, Won Suk Lee, Seung Joon Lee, Seul-Gi Kim, Jaekyung Cheon, Beodeul Kang, Chang Woo Kim, Hong Jae Chon, Chan Kim
Cancers.2022; 14(23): 5985. CrossRef
Prognostic factors for overall survival in patients with clear cell metastatic renal cell carcinoma
Dongrul Shin, Chang Wook Jeong, Cheryn Song, Minyong Kang, Seong Il Seo, Jung Kwon Kim, Hakmin Lee, Jinsoo Chung, Sung-Hoo Hong, Eu Chang Hwang, Cheol Kwak, Jae Young Park
Medicine.2021; 100(31): e26826. CrossRef
Efficacy and Prognostic Factors of Sunitinib as First-Line Therapy for Patients With Metastatic Renal Cell Carcinoma in an Arab Population
Ahmed Badran, Mahmoud A. Elshenawy, Amgad Shahin, Ali Aljubran, Ahmed Alzahrani, Abdelmoneim Eldali, Shouki Bazarbashi
JCO Global Oncology.2020; (6): 19. CrossRef
Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101
Motohide Uemura, Yoshihiko Tomita, Hideaki Miyake, Shingo Hatakeyama, Hiro‐omi Kanayama, Kazuyuki Numakura, Toshio Takagi, Tomoyuki Kato, Masatoshi Eto, Wataru Obara, Hirotsugu Uemura, Toni K. Choueiri, Robert J. Motzer, Yosuke Fujii, Yoichi Kamei, Yoshik
Cancer Science.2020; 111(3): 907. CrossRef
First-Line Axitinib Versus Sorafenib in Asian Patients with Metastatic Renal Cell Carcinoma: Exploratory Subgroup Analyses of Phase III Data
Xinan Sheng, Feng Bi, Xiubao Ren, Ying Cheng, Jinwan Wang, Brad Rosbrook, Ming Jiang, Jun Guo
Future Oncology.2019; 15(1): 53. CrossRef
The Roles of Common Variation and Somatic Mutation in Cancer Pharmacogenomics
Hiu Ting Chan, Yoon Ming Chin, Siew-Kee Low
Oncology and Therapy.2019; 7(1): 1. CrossRef
Risk of fatal adverse events in cancer patients treated with sunitinib
Bin Zhao, Hong Zhao, Jiaxin Zhao
Critical Reviews in Oncology/Hematology.2019; 137: 115. CrossRef
Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma
Jii Bum Lee, Hyung Soon Park, Sejung Park, Hyo Jin Lee, Kyung A Kwon, Young Jin Choi, Yu Jung Kim, Chung Mo Nam, Nam Hoon Cho, Beodeul Kang, Hyun Cheol Chung, Sun Young Rha
Cancer Research and Treatment.2019; 51(4): 1578. CrossRef
Stomatitis and VEGFR-Tyrosine Kinase Inhibitors (VR-TKIs): A Review of Current Literature in 4369 Patients
Claudia Arena, Giuseppe Troiano, Alfredo De Lillo, Nunzio F. Testa, Lorenzo Lo Muzio
BioMed Research International.2018; 2018: 1. CrossRef
Efficacy, safety, and prognostic indicators of first-line sunitinib in patients with metastatic renal cell carcinoma
Nahjatul Kursyiah Abd Ghafar, Adlinda Alip, Teng Aik Ong, Ning Yi Yap, Marniza Saad
Journal of Cancer Research and Therapeutics.2018; 14(6): 1303. CrossRef
Assessment of ethnic differences in sunitinib outcome between Caucasian and Asian patients with metastatic renal cell carcinoma: a meta-analysis
Xiaoyan Liu, Marta Fiocco, Jesse J. Swen, Henk-Jan Guchelaar
Acta Oncologica.2017; 56(4): 582. CrossRef
Oncogenic miR-100-5p is associated with cellular viability, migration and apoptosis in renal cell carcinoma
Peijie Chen, Canbin Lin, Jing Quan, Yulin Lai, Tao He, Liang Zhou, Xiang Pan, Xueling Wu, Yong Wang, Liangchao Ni, Shangqi Yang, Tao Wang, Yongqing Lai
Molecular Medicine Reports.2017; 16(4): 5023. CrossRef
miR‑660‑5p is associated with cell migration, invasion, proliferation and apoptosis in renal cell carcinoma
Tao He, Peijie Chen, Lu Jin, Jia Hu, Yifan Li, Liang Zhou, Shangqi Yang, Xiangming Mao, Yaoting Gui, Yun Chen, Yongqing Lai
Molecular Medicine Reports.2017;[Epub] CrossRef
Synergistic Survival: A New Phenomenon Connected to Adverse Events of First-Line Sunitinib Treatment in Advanced Renal Cell Carcinoma
Krisztián Nagyiványi, Barna Budai, Krisztina Bíró, Fruzsina Gyergyay, László Noszek, Zsófia Küronya, Hajnalka Németh, Péter Nagy, Lajos Géczi
Clinical Genitourinary Cancer.2016; 14(4): 314. CrossRef
BSA and ABCB1 polymorphism affect the pharmacokinetics of sunitinib and its active metabolite in Asian mRCC patients receiving an attenuated sunitinib dosing regimen
Jung-woo Chae, Yi Ling Teo, Han Kiat Ho, Jaeyeon Lee, Hyun-moon Back, Hwi-yeol Yun, Mats O. Karlsson, Kwang-il Kwon, Alexandre Chan
Cancer Chemotherapy and Pharmacology.2016; 78(3): 623. CrossRef
Key predictive factors for efficacy of axitinib in first-line metastatic renal cell carcinoma: subgroup analysis in Japanese patients from a randomized, double-blind phase II study
Yoshihiko Tomita, Satoshi Fukasawa, Mototsugu Oya, Hirotsugu Uemura, Nobuo Shinohara, Tomonori Habuchi, Brian I. Rini, Ying Chen, Angel H. Bair, Seiichiro Ozono, Seiji Naito, Hideyuki Akaza
Japanese Journal of Clinical Oncology.2016; 46(11): 1031. CrossRef
Association Study of a Functional Variant on ABCG2 Gene with Sunitinib-Induced Severe Adverse Drug Reaction
Siew-Kee Low, Koya Fukunaga, Atsushi Takahashi, Koichi Matsuda, Fumiya Hongo, Hiroyuki Nakanishi, Hiroshi Kitamura, Takamitsu Inoue, Yoichiro Kato, Yoshihiko Tomita, Satoshi Fukasawa, Tomoaki Tanaka, Kazuo Nishimura, Hirotsugu Uemura, Isao Hara, Masato Fu
PLOS ONE.2016; 11(2): e0148177. CrossRef
Sunitinib therapy for metastatic renal cell carcinoma: A urologist’s perspective
M Darrad, R Wilson
Journal of Clinical Urology.2016; 9(1): 32. CrossRef
Sunitinib treatment in patients with advanced renal cell cancer: the Brazilian National Cancer Institute (INCA) experience
Rafael Corrêa Coelho, Tomás Reinert, Franz Campos, Fábio Affonso Peixoto, Carlos Augusto de Andrade, Thalita Castro, Daniel Herchenhorn
International braz j urol.2016; 42(4): 694. CrossRef
Tumor suppressor miR-149-5p is associated with cellular migration, proliferation and apoptosis in renal cell carcinoma
LU JIN, YIFAN LI, JIAJU LIU, SHANGQI YANG, YAOTING GUI, XIANGMING MAO, GUOHUI NIE, YONGQING LAI
Molecular Medicine Reports.2016; 13(6): 5386. CrossRef
Efficacy and Safety of an Attenuated-Dose Sunitinib Regimen in Metastatic Renal Cell Carcinoma: Results From a Prospective Registry in Singapore
Hui Shan Tan, Huihua Li, Yu Wen Hong, Chee-Keong Toh, Alvin Wong, Gilberto Lopes, Miah Hiang Tay, Alexandre Chan, Xin Yao, Tiffany Tang, Quan Sing Ng, Ravindran Kanesvaran, Noan Minh Chau, Min-Han Tan
Clinical Genitourinary Cancer.2015; 13(4): e285. CrossRef
Central and Eastern European Experience with Sunitinib in Metastatic Renal Cell Carcinoma: A Sub-analysis of the Global Expanded-Access Trial
Eduard Vrdoljak, Lajos Géczi, Jozef Mardiak, Tudor-Eliade Ciuleanu, Sophie Leyman, Ke Zhang, Peter Sajben, Laszlo Torday
Pathology & Oncology Research.2015; 21(3): 775. CrossRef
Axitinib plasma pharmacokinetics and ethnic differences
Ying Chen, Akiyuki Suzuki, Michael A. Tortorici, May Garrett, Robert R. LaBadie, Yoshiko Umeyama, Yazdi K. Pithavala
Investigational New Drugs.2015; 33(2): 521. CrossRef
Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitors
Tomohiro Terada, Satoshi Noda, Ken-ichi Inui
Pharmacology & Therapeutics.2015; 152: 125. CrossRef
RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial
J.L. Lee, M.K. Kim, I. Park, J.-H. Ahn, D.H. Lee, H.M. Ryoo, C. Song, B. Hong, J.H. Hong, H. Ahn
Annals of Oncology.2015; 26(11): 2300. CrossRef
Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine‐refractory differentiated thyroid cancer
Naomi Kiyota, Martin Schlumberger, Kei Muro, Yuichi Ando, Shunji Takahashi, Yasukazu Kawai, Lori Wirth, Bruce Robinson, Steven Sherman, Takuya Suzuki, Katsuki Fujino, Anubha Gupta, Seiichi Hayato, Makoto Tahara
Cancer Science.2015; 106(12): 1714. CrossRef
Efficacy and Toxicity of Sunitinib in Metastatic Renal Cell Carcinoma Patients in Egypt
Wael Abdelgawad Edesa, Raafat Ragaey Abdelmalek
Asian Pacific Journal of Cancer Prevention.2015; 16(5): 1971. CrossRef
Induction of apoptotic cell death by betulin in multidrug-resistant human renal carcinoma cells
NAM-HUI YIM, YOUNG PIL JUNG, AEYUNG KIM, TAESOO KIM, JIN YEUL MA
Oncology Reports.2015; 34(2): 1058. CrossRef
Anti-VEGF therapy in mRCC: differences between Asian and non-Asian patients
Y Wang, T K Choueiri, J-L Lee, M-H Tan, S Y Rha, S A North, C K Kollmannsberger, D F McDermott, D Y C Heng
British Journal of Cancer.2014; 110(6): 1433. CrossRef
The Effect of ABCG2 Genotype on the Population Pharmacokinetics of Sunitinib in Patients With Renal Cell Carcinoma
Tomoyuki Mizuno, Masahide Fukudo, Tsuyoshi Fukuda, Tomohiro Terada, Min Dong, Tomomi Kamba, Toshinari Yamasaki, Osamu Ogawa, Toshiya Katsura, Ken-ichi Inui, Alexander A. Vinks, Kazuo Matsubara
Therapeutic Drug Monitoring.2014; 36(3): 310. CrossRef
Intolerance to Sunitinib Treatment in Hemodialysis Patients With Metastatic Renal Cell Carcinoma
Ibrahim Yildiz, Fatma Sen, Leyla Kilic, Rumeysa Ciftci, Mert Basaran
Korean Journal of Urology.2014; 55(1): 74. CrossRef
Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first‐line sunitinib: a medical chart review across ten centers in five European countries
Camillo Porta, Antonin Levy, Robert Hawkins, Daniel Castellano, Joaquim Bellmunt, Paul Nathan, Ray McDermott, John Wagstaff, Paul Donnellan, John McCaffrey, Francis Vekeman, Maureen P. Neary, Jose Diaz, Faisal Mehmud, Mei Sheng Duh
Cancer Medicine.2014; 3(6): 1517. CrossRef
Angiogenesis inhibitor therapies for advanced renal cell carcinoma: Toxicity and treatment patterns in clinical practice from a global medical chart review
WILLIAM K. OH, DAVID McDERMOTT, CAMILLO PORTA, ANTONIN LEVY, REZA ELAIDI, FLORIAN SCOTTE, ROBERT HAWKINS, DANIEL CASTELLANO, JOAQUIM BELLMUNT, SUN YOUNG RHA, JONG-MU SUN, PAUL NATHAN, BRUCE A. FEINBERG, JEFFREY SCOTT, RAY McDERMOTT, JIN-HEE AHN, JOHN WAGS
International Journal of Oncology.2014; 44(1): 5. CrossRef
Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma
R J Motzer, B Escudier, R Bukowski, B I Rini, T E Hutson, C H Barrios, X Lin, K Fly, E Matczak, M E Gore
British Journal of Cancer.2013; 108(12): 2470. CrossRef
Therapy management with sunitinib in patients with metastatic renal cell carcinoma: Key concepts and the impact of clinical biomarkers
Daniel Castellano, Alain Ravaud, Manuela Schmidinger, Guillermo De Velasco, Federico Vazquez
Cancer Treatment Reviews.2013; 39(3): 230. CrossRef
Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients
Hye Ryun Kim, Hyung Soon Park, Woo Sun Kwon, Ji Hyun Lee, Yusuke Tanigawara, Sun Min Lim, Hyo Song Kim, Sang Jun Shin, Jung Bae Ahn, Sun Young Rha
Cancer Chemotherapy and Pharmacology.2013; 72(4): 825. CrossRef
Validation of the MSKCC and Heng Risk Criteria Models for Predicting Survival in Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib
Whi-An Kwon, In-Chang Cho, Ami Yu, Byung-Ho Nam, Jae Young Joung, Ho Kyung Seo, Kang Hyun Lee, Jinsoo Chung
Annals of Surgical Oncology.2013; 20(13): 4397. CrossRef
Efficacy and safety of everolimus in Korean patients with metastatic renal cell carcinoma
Ki Hyang Kim, Sang Hyun Yoon, Hae-Jung Lee, Hyo Song Kim, Sang Joon Shin, Joong Bae Ahn, Sun Young Rha
Cancer Chemotherapy and Pharmacology.2013; 72(4): 853. CrossRef
Safety and treatment patterns of angiogenesis inhibitors in patients with advanced renal cell carcinoma in Spain
Daniel Castellano, Mei Sheng Duh, Caroline Korves, Ellison Dial Suthoff, Maureen Neary, Luis Javier Hernández Pastor, Joaquim Bellmunt
Expert Opinion on Drug Safety.2013; 12(4): 455. CrossRef
Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib
Aiping Zhou, Wen Zhang, Chunxiao Chang, Xiaoyan Chen, Dafang Zhong, Qiong Qin, Donghua Lou, Haoyuan Jiang, Jinwan Wang
Cancer Chemotherapy and Pharmacology.2013; 72(5): 1043. CrossRef
Analysis of the Reasons for Dose Reduction or Discontinuation of Sunitinib in Korean Patients
노지혜, 이주연, 이혜숙, 김향숙, 강래영, 이용화
Journal of Korean Society of Health-System Pharmacists.2013; 30(3): 210. CrossRef
Effect of P-Glycoprotein and Breast Cancer Resistance Protein Inhibition on the Pharmacokinetics of Sunitinib in Rats
Sachiko Kunimatsu, Tomoyuki Mizuno, Masahide Fukudo, Toshiya Katsura
Drug Metabolism and Disposition.2013; 41(8): 1592. CrossRef
Famitinib in metastatic renal cell carcinoma: a single center study
Wen ZHANG, Ai-Ping ZHOU, Qiong QIN, Chun-Xiao CHANG, Hao-Yuan JIANG, Jian-Hui MA, Jin-Wan WANG
Chinese Medical Journal.2013; 126(22): 4277. CrossRef
Management of sunitinib adverse events in renal cell carcinoma patients: The Asian experience
Aiping ZHOU
Asia-Pacific Journal of Clinical Oncology.2012; 8(2): 132. CrossRef
Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients
Dok Hyun Yoon, Min-Hee Ryu, Baek-Yeol Ryoo, Moyeol Beck, Dae Ro Choi, Yoojin Cho, Jae-Lyun Lee, Heung-Moon Chang, Tae Won Kim, Yoon-Koo Kang
Investigational New Drugs.2012; 30(2): 819. CrossRef
Current Status of Targeted Therapy for Advanced Renal Cell Carcinoma
In-Chang Cho, Jinsoo Chung
Korean Journal of Urology.2012; 53(4): 217. CrossRef
Impact of Genetic Variation in Breast Cancer Resistance Protein (BCRP/ABCG2) on Sunitinib Pharmacokinetics
Tomoyuki Mizuno, Masahide Fukudo, Tomohiro Terada, Tomomi Kamba, Eijiro Nakamura, Osamu Ogawa, Ken-ichi Inui, Toshiya Katsura
Drug Metabolism and Pharmacokinetics.2012; 27(6): 631. CrossRef
Response Rates and Adverse Effects of Continuous Once-daily Sunitinib in Patients with Advanced Renal Cell Carcinoma: A Single-center Study in Turkey
I. Yildiz, F. Sen, M. Basaran, M. Ekenel, F. Agaoglu, E. Darendeliler, H. M. Tunc, F. Ozcan, S. Bavbek
Japanese Journal of Clinical Oncology.2011; 41(12): 1380. CrossRef
Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: A phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma
Yoshihiko Tomita, Hirotsugu Uemura, Hiroyuki Fujimoto, Hiro-omi Kanayama, Nobuo Shinohara, Hayakazu Nakazawa, Keiji Imai, Yoshiko Umeyama, Seiichiro Ozono, Seiji Naito, Hideyuki Akaza
European Journal of Cancer.2011; 47(17): 2592. CrossRef
Efficacy and Safety of Sunitinib on Metastatic Renal Cell Carcinoma: A Single-Institution Experience
Eugene Hwang, Hyo Jin Lee, Chong Koo Sul, Jae Sung Lim
Korean Journal of Urology.2010; 51(7): 450. CrossRef
Kidney Cancer Working Group Report
S. Naito, Y. Tomita, S. Y. Rha, H. Uemura, M. Oya, H. Z. Song, L. H. Zhong, M. I. B. A. Wahid
Japanese Journal of Clinical Oncology.2010; 40(Supplement): i51. CrossRef
Hematologic Toxicity in Patients Treated with Sunitinib for Advanced Thyroid Cancer
Anastasios Gkountouvas, Ifigeneia Kostoglou-Athanassiou, Eirini Veniou, Panagiotis Repousis, Nikolaos Ziras, Philippos Kaldrimidis
Thyroid.2010; 20(6): 597. CrossRef
The Efficacy and Safety of Sunitinib in Korean Patients with Advanced Renal Cell Carcinoma: High Incidence of Toxicity Leads to Frequent Dose Reduction
C. Yoo, J. E. Kim, J.-L. Lee, J.-H. Ahn, D. H. Lee, J.-S. Lee, S. Na, C.-S. Kim, J. H. Hong, B. Hong, C. Song, H. Ahn
Japanese Journal of Clinical Oncology.2010; 40(10): 980. CrossRef
Novel Sunitinib Strategy in Metastatic Renal Cell Carcinoma on Hemodialysis: Intermittent Dose of Sunitinib after Hemodialysis
Sang Hyun Yoon, Ki Hyang Kim, Junjeong Choi, Gun Min Kim, Joo Hoon Kim, Hyo Song Kim, Young Nyun Park, Sun Young Rha
Cancer Research and Treatment.2010; 42(3): 180. CrossRef
Comparative Analysis between Immunochemotherapy and Target Therapy for Metastatic Renal Cell Carcinoma: Overview of Treatment-Related Adverse Events and the Dropout Rate in Korea
Jee Han Lee, Sung-Goo Chang, Seung Hyun Jeon, Gyeong Eun Min, Koo Han Yoo
Korean Journal of Urology.2010; 51(6): 379. CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Treatment Outcomes of Sunitinib Treatment in Advanced Renal Cell Carcinoma Patients: A Single Cancer Center Experience in Korea

Cancer Res Treat. 2009;41(2):67-72. Published online June 30, 2009

DOI: https://doi.org/10.4143/crt.2009.41.2.67

XML Download

Abstract
Introduction
Materials and Methods
Results
Discussion
Conclusion
NOTES
REFERENCES

Treatment Outcomes of Sunitinib Treatment in Advanced Renal Cell Carcinoma Patients: A Single Cancer Center Experience in Korea

Fig. 1 Progression-free survival in Korean patients with metastatic renal cell carcinoma.

Fig. 2 Overall survival in Korean patients with metastatic renal cell carcinoma.

Fig. 1

Fig. 2

Treatment Outcomes of Sunitinib Treatment in Advanced Renal Cell Carcinoma Patients: A Single Cancer Center Experience in Korea

Table 1

Patient characteristics

Table 2

Best tumor response^*

^*Tumor response was assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST).

Table 3

Treatment-related adverse events

^*These data were available on selected 45 patients.

Table 4

Treatment-related laboratory abnormalities

Table 1 Patient characteristics

Table 2 Best tumor response*

^*Tumor response was assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST).

Table 3 Treatment-related adverse events

^*These data were available on selected 45 patients.

Table 4 Treatment-related laboratory abnormalities